Diabetology

India is the 'Diabetes capital of the world', according to a study by the Indian Council of Medical Research that shows the country now has 101 million diabetics, with a further 136 million pre-diabetic individuals¹, Diabetic cases have increased by 44 percent in four years from 70 million affected people in 2019

The average age of onset is 42.5 years. Nearly 1 million Indians die due to diabetes every year. We have a noteworthy presence in the Diabetes Therapy Area (TA) through our Diabetology and Metabolic Division. This reinforces our commitment to helping patients manage their diabetes better and improve the quality of their lives. Our leading products in this segment are Glucoryl range (Glucoryl, Glucoryl M, Glucoryl MV), Dapanorm range (Dapanorm, Dapanorm M, Dapanorm Duo, Dapanorm Trio), Alsita range (Alsita, Alsita M, Alsita MP), Euclide range (Euclide-XR, Euclide – M), Gluvilda range (Gluvilda – M, Gluvilda OD), Olymprix range (Olymprix M and Olymprix). Moreover, we have exclusivity to market Evogliptin(Valera, Valera M) in India. Our aim is to be a leading player in Diabetes Therapy by providing high-quality and affordable solutions to millions of diabetics across India.

Our aim is to be a key player in Diabetes Therapy by providing affordable solutions to millions of diabetics across India.

Reference : 1. Lancet Diabetes Endocrinol 2023; 11: 474–89